张丽红;邓子淳;方佳;李兰洲;刘艳;

• 1:吉林大学基础医学院
• 2:吉林大学生命科学学院

摘要(Abstract)：

目的利用痛风动物模型对异落新妇苷(IA)抗痛风活性及作用机制进行研究。方法关节腔内注射尿酸钠(MSU)建立痛风性关节炎大鼠模型,通过踝关节肿胀变化及炎症相关因子测定,评价异落新妇苷抗痛风性关节炎活性;腹腔注射氧嗪酸钾建立高尿酸血症小鼠模型,通过血尿酸(UA)含量,黄嘌呤氧化酶(XOD)活性测定,评价异落新妇苷抗高尿酸血症活性。结果异落新妇苷治疗显著降低了痛风性关节炎大鼠关节肿胀5.7%以上,同时炎症因子IL-1β、IL-8、MCP-1、IFN-γ显著降低(P <0.05),并能有效的降低炎症细胞浸润;同时异落新妇苷治疗显著降低了高尿酸血症小鼠血清UA 25.8%以上和XOD活性12.9%以上。结论异落新妇苷可以通过降低炎症水平实现对痛风性关节炎的抑制,并通过抑制XOD活性,降低血UA水平实现抗高尿酸血症活性。

关键词(KeyWords)： 痛风;异落新妇苷;抗炎;高尿酸血症

Abstract:

Keywords:

基金项目(Foundation): 吉林省省校共建计划生物医药专项(SXGJSF2017-1)

作者(Author): 张丽红;邓子淳;方佳;李兰洲;刘艳;

Email:

DOI:

参考文献(References)：

• [1]SCHLESINGER N,SCHUMACHER R,CATTON M,et al.Colchicine for acute gout[J].American family physician,2015,91(11):759-760.
• [2]Lesinurad/allopurinol(Duzallo)for gout-associated hyperuricemia[J].Medical Letter on Drugs&Therapeutics,2017,59(1533):182.
• [3]赵家敏.不同剂量秋水仙碱治疗急性痛风性关节炎疗效观察[J].中国实用乡村医生杂志,2005,12(1):35.
• [4]HANDE K R,NOONE R M,STONE W J.Severe allopurinol toxicity.Description and guidelines for prevention in patients with renal insufficiency[J].American Journal of Medicine,1984,76(1):47-56.
• [5]LU C L,ZHU W,WANG M,et al.Antioxidant and AntiInflammatory Activities of Phenolic-Enriched Extracts of Smilax glabra[J].Evidence-Based Complementary and Alternative Medicine,2014:8.
• [6]刘东平,廖启元,刘娱姗.土茯苓中落新妇苷含量测定方法改进的研究[J].泸州医学院学报,2016,39(2):141-144.
• [7]陆弘,周福军,单淇,等.黄杞叶化学成分的分离与鉴定[J].沈阳药科大学学报,2016,33(12):945-949.
• [8]刘金畅,王涛.萆薢、土茯苓治疗高尿酸血症研究进展[J].辽宁中医药大学学报,2018,20(1):79-81.
• [9]金晓敏,张晓熙,郭璐,等.基于NLRP3炎性体轴探讨土茯苓总黄酮对痛风性关节炎的作用和机制[J].中国实验方剂学杂志,2018,24(4):90-95.
• [10]SCHUMACHER H R,BECKER M A,PALO W A,et al.Tophaceous gout:Quantitative evaluation by direct physical measurement[J].Journal of Rheumatology,2005,32(12):2368-2372.
• [11]律广富,仇志凯,常诗卓,等.玉米须总黄酮提取物对痛风性肾病大鼠肾脏尿酸排泄的影响[J].中成药,2018,40(6):1373-1376.
• [12]SO A,DE SMEDT T,REVAZ S,et al.A pilot study of IL-1inhibition by anakinra in acute gout[J].Arthritis Research&Therapy,2007,9(2):6.
• [13]VLAHOPOULOS S,BOLDOGH I,CASOLA A,et al.Nuclear factor-kappa B-dependent induction of interleukin-8gene expression by tumor necrosis factor alpha:Evidence for an antioxidant sensitive activating pathway distinct from nuclear translocation[J].Blood,1999,94(6):1878-1889.
• [14]XIA M D,SUI Z H.Recent developments in CCR2antagonists[J].Expert Opin Ther Pat,2009,19(3):295-303.
• [15]GREENHILL C J,JONES G W,NOWELL M A,et al.Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction[J].Arthritis Research&Therapy,2014,16(4):10.
• [16]IP W K E,HOSHI N,SHOUVAL D S,et al.Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages[J].Science,2017,356(6337):513-519.
• [17]WU X W,LEE C C,MUZNY D M,et al.Urate oxidase:primary structure and evolutionary implications[J].Proc Natl Acad Sci U S A,1989,86(23):9412-9416.
• [18]MENESHIAN A,BULKLEY G B.The physiology of endothelial xanthine oxidase:From urate catabolism to reperfusion injury to inflammatory signal transduction[J].Microcirculation,2002,9(3):161-175.